Loading…

6ER-026 Spectrum of heart failure in 16 sub-Saharan African countries: treatments and in-hospital outcome

Background and ImportanceHeart failure (HF) is the most common primary diagnosis for patients admitted to hospital with heart disease in sub-Saharan Africa (SSA). However, little is known about the management of HF in hospitalisation in SSA.Aim and ObjectivesTo describe in hospital drugs strategies...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2023-03, Vol.30 (Suppl 1), p.A167-A168
Main Authors: Cavagna, P, Kouam Kouam, C, Diop, IB, Limbole, E, Allawaye, L, Takombe, JL, Traore, AK, N’Guetta, R, Ikama, MS, Jouven, X, Antignac, M
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page A168
container_issue Suppl 1
container_start_page A167
container_title European journal of hospital pharmacy. Science and practice
container_volume 30
creator Cavagna, P
Kouam Kouam, C
Diop, IB
Limbole, E
Allawaye, L
Takombe, JL
Traore, AK
N’Guetta, R
Ikama, MS
Jouven, X
Antignac, M
description Background and ImportanceHeart failure (HF) is the most common primary diagnosis for patients admitted to hospital with heart disease in sub-Saharan Africa (SSA). However, little is known about the management of HF in hospitalisation in SSA.Aim and ObjectivesTo describe in hospital drugs strategies to manage HF in 36 cardiovascular (CV) departments.Material and MethodsWe conducted a transversal and longitudinal study in CV departments of 36 hospital (public and private) in 16 SSA countries. The February study is an ongoing observatory included all inpatients in February from each year since 2016. Data including socio-demographic and clinical characteristics, CV risk factors, causes of admission, medication and length of stay were collected during hospitalisation by physicians. Patient wealth index was assessed by physicians as low, middle and high according to patient capacity to afford hospitalisation. All analyses were performed with random effect on countries and through scripts developed in the R software 4.0.3.ResultsOverall, 2084 patients were admitted for HF in the February study. HF representing 47.9% of all patients included. The mean age was 57 ± 17.4 years and 53.8% were men. Proportions of patients admitted for HF varied across countries from 21.4% in Burundi to 66% in Congo (p
doi_str_mv 10.1136/ejhpharm-2023-eahp.349
format article
fullrecord <record><control><sourceid>proquest_bmj_j</sourceid><recordid>TN_cdi_proquest_journals_2789644418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2789644418</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1199-40198eefb9a876a9dfb154442181647f3891b0340556148c695942e6d50d6d0f3</originalsourceid><addsrcrecordid>eNpFkMtKAzEUhoMoWGpfQQKuU3OfxF0p9QKCYHUdMjMJM7VzMcns3fiiPokp9bL6z-I75z98AFwSvCSEyWu3a8bGhg5RTBlythmXjOsTMKOYF0hryU__ZiHPwSLGtsSCMaU50zPwJjfPCFP59fG5HV2VwtTBwcPG2ZCgt-1-Cg62PSQSxqlEW5vLbA9XPrRVzmqY-hRaF29gCs6mzvUpQtvXeQc1QxzbZPdwmFI1dO4CnHm7j27xk3Pwert5Wd-jx6e7h_XqEZWEaI04Jlo550ttVSGtrn1JBOecEkUkL3x-nZSYcSyEJFxVUgvNqZO1wLWssWdzcHW8O4bhfXIxmd0whT5XGlqorIRzojJFj1TZ7f4Bgs3Bq_n1ag5ezcGryV7ZN52_blM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2789644418</pqid></control><display><type>article</type><title>6ER-026 Spectrum of heart failure in 16 sub-Saharan African countries: treatments and in-hospital outcome</title><source>PubMed Central</source><creator>Cavagna, P ; Kouam Kouam, C ; Diop, IB ; Limbole, E ; Allawaye, L ; Takombe, JL ; Traore, AK ; N’Guetta, R ; Ikama, MS ; Jouven, X ; Antignac, M</creator><creatorcontrib>Cavagna, P ; Kouam Kouam, C ; Diop, IB ; Limbole, E ; Allawaye, L ; Takombe, JL ; Traore, AK ; N’Guetta, R ; Ikama, MS ; Jouven, X ; Antignac, M</creatorcontrib><description>Background and ImportanceHeart failure (HF) is the most common primary diagnosis for patients admitted to hospital with heart disease in sub-Saharan Africa (SSA). However, little is known about the management of HF in hospitalisation in SSA.Aim and ObjectivesTo describe in hospital drugs strategies to manage HF in 36 cardiovascular (CV) departments.Material and MethodsWe conducted a transversal and longitudinal study in CV departments of 36 hospital (public and private) in 16 SSA countries. The February study is an ongoing observatory included all inpatients in February from each year since 2016. Data including socio-demographic and clinical characteristics, CV risk factors, causes of admission, medication and length of stay were collected during hospitalisation by physicians. Patient wealth index was assessed by physicians as low, middle and high according to patient capacity to afford hospitalisation. All analyses were performed with random effect on countries and through scripts developed in the R software 4.0.3.ResultsOverall, 2084 patients were admitted for HF in the February study. HF representing 47.9% of all patients included. The mean age was 57 ± 17.4 years and 53.8% were men. Proportions of patients admitted for HF varied across countries from 21.4% in Burundi to 66% in Congo (p&lt;0.01). Average length of stay in hospitals was 11 days and mortality rate was 13%. Among HF patients, 74% of patients had CV risk factors and hypertension was reported in 55.8% of patients. During hospitalisation, 88.8% of patients were treated with diuretics followed by angiotensin-converting enzyme inhibitors (ACEI) (61.8%), anticoagulant (47.8%) and beta blockers (BB) (34.6%) (figure). Monotherapy were used in 14%, combination of two drugs, three drugs and four drugs strategies were used in 35%, 33% 12% respectively. Diuretics were mostly prescribed in patient with low wealth index whereas ACEI, BB and anticoagulant in high wealth index (p&lt;0.05).Abstract 6ER-026 Figure 1Conclusion and RelevanceHF treatment access varied significantly across countries and according to patient wealth index.References and/or AcknowledgementsConflict of InterestNo conflict of interest.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2023-eahp.349</identifier><language>eng</language><publisher>London: British Medical Journal Publishing Group</publisher><subject>Anticoagulants ; Conflicts of interest ; Diuretics ; Drugs ; Heart failure ; Hospitalization ; Length of stay ; Patients ; Section 6: Education and research</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A167-A168</ispartof><rights>European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2023 European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Cavagna, P</creatorcontrib><creatorcontrib>Kouam Kouam, C</creatorcontrib><creatorcontrib>Diop, IB</creatorcontrib><creatorcontrib>Limbole, E</creatorcontrib><creatorcontrib>Allawaye, L</creatorcontrib><creatorcontrib>Takombe, JL</creatorcontrib><creatorcontrib>Traore, AK</creatorcontrib><creatorcontrib>N’Guetta, R</creatorcontrib><creatorcontrib>Ikama, MS</creatorcontrib><creatorcontrib>Jouven, X</creatorcontrib><creatorcontrib>Antignac, M</creatorcontrib><title>6ER-026 Spectrum of heart failure in 16 sub-Saharan African countries: treatments and in-hospital outcome</title><title>European journal of hospital pharmacy. Science and practice</title><addtitle>Eur J Hosp Pharm</addtitle><description>Background and ImportanceHeart failure (HF) is the most common primary diagnosis for patients admitted to hospital with heart disease in sub-Saharan Africa (SSA). However, little is known about the management of HF in hospitalisation in SSA.Aim and ObjectivesTo describe in hospital drugs strategies to manage HF in 36 cardiovascular (CV) departments.Material and MethodsWe conducted a transversal and longitudinal study in CV departments of 36 hospital (public and private) in 16 SSA countries. The February study is an ongoing observatory included all inpatients in February from each year since 2016. Data including socio-demographic and clinical characteristics, CV risk factors, causes of admission, medication and length of stay were collected during hospitalisation by physicians. Patient wealth index was assessed by physicians as low, middle and high according to patient capacity to afford hospitalisation. All analyses were performed with random effect on countries and through scripts developed in the R software 4.0.3.ResultsOverall, 2084 patients were admitted for HF in the February study. HF representing 47.9% of all patients included. The mean age was 57 ± 17.4 years and 53.8% were men. Proportions of patients admitted for HF varied across countries from 21.4% in Burundi to 66% in Congo (p&lt;0.01). Average length of stay in hospitals was 11 days and mortality rate was 13%. Among HF patients, 74% of patients had CV risk factors and hypertension was reported in 55.8% of patients. During hospitalisation, 88.8% of patients were treated with diuretics followed by angiotensin-converting enzyme inhibitors (ACEI) (61.8%), anticoagulant (47.8%) and beta blockers (BB) (34.6%) (figure). Monotherapy were used in 14%, combination of two drugs, three drugs and four drugs strategies were used in 35%, 33% 12% respectively. Diuretics were mostly prescribed in patient with low wealth index whereas ACEI, BB and anticoagulant in high wealth index (p&lt;0.05).Abstract 6ER-026 Figure 1Conclusion and RelevanceHF treatment access varied significantly across countries and according to patient wealth index.References and/or AcknowledgementsConflict of InterestNo conflict of interest.</description><subject>Anticoagulants</subject><subject>Conflicts of interest</subject><subject>Diuretics</subject><subject>Drugs</subject><subject>Heart failure</subject><subject>Hospitalization</subject><subject>Length of stay</subject><subject>Patients</subject><subject>Section 6: Education and research</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpFkMtKAzEUhoMoWGpfQQKuU3OfxF0p9QKCYHUdMjMJM7VzMcns3fiiPokp9bL6z-I75z98AFwSvCSEyWu3a8bGhg5RTBlythmXjOsTMKOYF0hryU__ZiHPwSLGtsSCMaU50zPwJjfPCFP59fG5HV2VwtTBwcPG2ZCgt-1-Cg62PSQSxqlEW5vLbA9XPrRVzmqY-hRaF29gCs6mzvUpQtvXeQc1QxzbZPdwmFI1dO4CnHm7j27xk3Pwert5Wd-jx6e7h_XqEZWEaI04Jlo550ttVSGtrn1JBOecEkUkL3x-nZSYcSyEJFxVUgvNqZO1wLWssWdzcHW8O4bhfXIxmd0whT5XGlqorIRzojJFj1TZ7f4Bgs3Bq_n1ag5ezcGryV7ZN52_blM</recordid><startdate>20230323</startdate><enddate>20230323</enddate><creator>Cavagna, P</creator><creator>Kouam Kouam, C</creator><creator>Diop, IB</creator><creator>Limbole, E</creator><creator>Allawaye, L</creator><creator>Takombe, JL</creator><creator>Traore, AK</creator><creator>N’Guetta, R</creator><creator>Ikama, MS</creator><creator>Jouven, X</creator><creator>Antignac, M</creator><general>British Medical Journal Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>K9.</scope></search><sort><creationdate>20230323</creationdate><title>6ER-026 Spectrum of heart failure in 16 sub-Saharan African countries: treatments and in-hospital outcome</title><author>Cavagna, P ; Kouam Kouam, C ; Diop, IB ; Limbole, E ; Allawaye, L ; Takombe, JL ; Traore, AK ; N’Guetta, R ; Ikama, MS ; Jouven, X ; Antignac, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1199-40198eefb9a876a9dfb154442181647f3891b0340556148c695942e6d50d6d0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anticoagulants</topic><topic>Conflicts of interest</topic><topic>Diuretics</topic><topic>Drugs</topic><topic>Heart failure</topic><topic>Hospitalization</topic><topic>Length of stay</topic><topic>Patients</topic><topic>Section 6: Education and research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cavagna, P</creatorcontrib><creatorcontrib>Kouam Kouam, C</creatorcontrib><creatorcontrib>Diop, IB</creatorcontrib><creatorcontrib>Limbole, E</creatorcontrib><creatorcontrib>Allawaye, L</creatorcontrib><creatorcontrib>Takombe, JL</creatorcontrib><creatorcontrib>Traore, AK</creatorcontrib><creatorcontrib>N’Guetta, R</creatorcontrib><creatorcontrib>Ikama, MS</creatorcontrib><creatorcontrib>Jouven, X</creatorcontrib><creatorcontrib>Antignac, M</creatorcontrib><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cavagna, P</au><au>Kouam Kouam, C</au><au>Diop, IB</au><au>Limbole, E</au><au>Allawaye, L</au><au>Takombe, JL</au><au>Traore, AK</au><au>N’Guetta, R</au><au>Ikama, MS</au><au>Jouven, X</au><au>Antignac, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>6ER-026 Spectrum of heart failure in 16 sub-Saharan African countries: treatments and in-hospital outcome</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><stitle>Eur J Hosp Pharm</stitle><date>2023-03-23</date><risdate>2023</risdate><volume>30</volume><issue>Suppl 1</issue><spage>A167</spage><epage>A168</epage><pages>A167-A168</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>Background and ImportanceHeart failure (HF) is the most common primary diagnosis for patients admitted to hospital with heart disease in sub-Saharan Africa (SSA). However, little is known about the management of HF in hospitalisation in SSA.Aim and ObjectivesTo describe in hospital drugs strategies to manage HF in 36 cardiovascular (CV) departments.Material and MethodsWe conducted a transversal and longitudinal study in CV departments of 36 hospital (public and private) in 16 SSA countries. The February study is an ongoing observatory included all inpatients in February from each year since 2016. Data including socio-demographic and clinical characteristics, CV risk factors, causes of admission, medication and length of stay were collected during hospitalisation by physicians. Patient wealth index was assessed by physicians as low, middle and high according to patient capacity to afford hospitalisation. All analyses were performed with random effect on countries and through scripts developed in the R software 4.0.3.ResultsOverall, 2084 patients were admitted for HF in the February study. HF representing 47.9% of all patients included. The mean age was 57 ± 17.4 years and 53.8% were men. Proportions of patients admitted for HF varied across countries from 21.4% in Burundi to 66% in Congo (p&lt;0.01). Average length of stay in hospitals was 11 days and mortality rate was 13%. Among HF patients, 74% of patients had CV risk factors and hypertension was reported in 55.8% of patients. During hospitalisation, 88.8% of patients were treated with diuretics followed by angiotensin-converting enzyme inhibitors (ACEI) (61.8%), anticoagulant (47.8%) and beta blockers (BB) (34.6%) (figure). Monotherapy were used in 14%, combination of two drugs, three drugs and four drugs strategies were used in 35%, 33% 12% respectively. Diuretics were mostly prescribed in patient with low wealth index whereas ACEI, BB and anticoagulant in high wealth index (p&lt;0.05).Abstract 6ER-026 Figure 1Conclusion and RelevanceHF treatment access varied significantly across countries and according to patient wealth index.References and/or AcknowledgementsConflict of InterestNo conflict of interest.</abstract><cop>London</cop><pub>British Medical Journal Publishing Group</pub><doi>10.1136/ejhpharm-2023-eahp.349</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2047-9956
ispartof European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A167-A168
issn 2047-9956
2047-9964
language eng
recordid cdi_proquest_journals_2789644418
source PubMed Central
subjects Anticoagulants
Conflicts of interest
Diuretics
Drugs
Heart failure
Hospitalization
Length of stay
Patients
Section 6: Education and research
title 6ER-026 Spectrum of heart failure in 16 sub-Saharan African countries: treatments and in-hospital outcome
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T13%3A32%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_j&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=6ER-026%E2%80%85Spectrum%20of%20heart%20failure%20in%2016%20sub-Saharan%20African%20countries:%20treatments%20and%20in-hospital%20outcome&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Cavagna,%20P&rft.date=2023-03-23&rft.volume=30&rft.issue=Suppl%201&rft.spage=A167&rft.epage=A168&rft.pages=A167-A168&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2023-eahp.349&rft_dat=%3Cproquest_bmj_j%3E2789644418%3C/proquest_bmj_j%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b1199-40198eefb9a876a9dfb154442181647f3891b0340556148c695942e6d50d6d0f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2789644418&rft_id=info:pmid/&rfr_iscdi=true